Literature DB >> 3732365

Ceftriaxone pharmacokinetics during peritoneal dialysis.

J R Koup, E Keller, H Neumann, K Stoeckel.   

Abstract

The purpose of this study was to investigate the pharmacokinetics of intraperitoneally (IP) administered ceftriaxone (CRO) in patients maintained on chronic peritoneal dialysis. A single 2 g dose of CRO was administered IP to six adult patients who did not have peritonitis at the time of study. After a 5 hour dwell, the peritoneal fluid was exchanged with CRO-free fluid. Exchanges were carried out every 4 to 8 h, over a 24- to 28-h period. The peak total plasma CRO concentration was 104 micrograms/ml. An average of 74.1% of the IP dose of CRO was absorbed. Plasma protein binding was nonlinear; mean free fraction ranged from 12.8 to 17.9% at low and high concentrations. Dialysate concentrations at the end of subsequent exchanges ranged from means of 19.9 to 2.9 micrograms/ml. Total CRO clearance from plasma was 10.1 ml X kg-1 X h-1 and the mean terminal t 1/2 was 12.7 h. Dialytic clearance averaged 0.69 ml X kg-1 X h-1, only 6.9% of total clearance. A model which incorporates known characteristics of CRO binding and distribution in anuric patients was used to simulate plasma and peritoneal concentrations of CRO during multiple dose IP drug administration.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3732365     DOI: 10.1007/bf00541533

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  10 in total

1.  Continuous ambulatory peritoneal dialysis: a new era in the treatment of chronic renal failure.

Authors:  D G Oreopoulos; M Robson; B Faller; R Ogilvie; A Rapoport; G A deVeber
Journal:  Clin Nephrol       Date:  1979-03       Impact factor: 0.975

2.  Numerical solution of nonlinear pharmacokinetic equations: effects of plasma protein binding on drug distribution and elimination.

Authors:  J J Coffey; F J Bullock; P T Schoenemann
Journal:  J Pharm Sci       Date:  1971-11       Impact factor: 3.534

3.  Single-dose ceftriaxone kinetics in functionally anephric patients.

Authors:  K Stoeckel; P J McNamara; G Hoppe-Seyler; A Blumberg; E Keller
Journal:  Clin Pharmacol Ther       Date:  1983-05       Impact factor: 6.875

4.  A distributed model of peritoneal-plasma transport: theoretical considerations.

Authors:  M F Flessner; R L Dedrick; J S Schultz
Journal:  Am J Physiol       Date:  1984-04

5.  Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis.

Authors:  T Y Ti; L Fortin; J H Kreeft; D S East; R I Ogilvie; P J Somerville
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

6.  Ro 13-9904, a long-acting broad-spectrum cephalosporin: in vitro and in vivo studies.

Authors:  P Angehrn; P J Probst; R Reiner; R L Then
Journal:  Antimicrob Agents Chemother       Date:  1980-12       Impact factor: 5.191

7.  Peritonitis during continuous ambulatory peritoneal dialysis.

Authors:  J Rubin; W A Rogers; H M Taylor; E D Everett; B F Prowant; L V Fruto; K D Nolph
Journal:  Ann Intern Med       Date:  1980-01       Impact factor: 25.391

8.  Effects of concentration-dependent plasma protein binding on ceftriaxone kinetics.

Authors:  K Stoeckel; P J McNamara; R Brandt; H Plozza-Nottebrock; W H Ziegler
Journal:  Clin Pharmacol Ther       Date:  1981-05       Impact factor: 6.875

9.  Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model.

Authors:  K Stoeckel; J R Koup
Journal:  Am J Med       Date:  1984-10-19       Impact factor: 4.965

Review 10.  Antimicrobial activity of ceftriaxone: a review.

Authors:  R Cleeland; E Squires
Journal:  Am J Med       Date:  1984-10-19       Impact factor: 4.965

  10 in total
  8 in total

1.  Pharmacokinetics of cefepime in patients undergoing continuous ambulatory peritoneal dialysis.

Authors:  R H Barbhaiya; C A Knupp; M Pfeffer; D Zaccardelli; G M Dukes; W Mattern; K A Pittman; L J Hak
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

Review 2.  Drug therapy in patients undergoing continuous ambulatory peritoneal dialysis. Clinical pharmacokinetic considerations.

Authors:  E Keller; P Reetze; P Schollmeyer
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

Review 3.  Drug dosage in patients during continuous renal replacement therapy. Pharmacokinetic and therapeutic considerations.

Authors:  P Reetze-Bonorden; J Böhler; E Keller
Journal:  Clin Pharmacokinet       Date:  1993-05       Impact factor: 6.447

Review 4.  Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections.

Authors:  Harriet M Lamb; Douglas Ormrod; Lesley J Scott; David P Figgitt
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 5.  Ceftriaxone. A reappraisal of its antibacterial activity and pharmacokinetic properties, and an update on its therapeutic use with particular reference to once-daily administration.

Authors:  R N Brogden; A Ward
Journal:  Drugs       Date:  1988-06       Impact factor: 9.546

Review 6.  Cefepime clinical pharmacokinetics.

Authors:  M P Okamoto; R K Nakahiro; A Chin; A Bedikian
Journal:  Clin Pharmacokinet       Date:  1993-08       Impact factor: 6.447

Review 7.  Clinical pharmacokinetics of ceftriaxone.

Authors:  J H Yuk; C H Nightingale; R Quintiliani
Journal:  Clin Pharmacokinet       Date:  1989-10       Impact factor: 6.447

8.  Ceftriaxone-induced acute encephalopathy in a peritoneal dialysis patient.

Authors:  Sami Safadi; Michael Mao; John J Dillon
Journal:  Case Rep Nephrol       Date:  2014-12-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.